Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study

被引:1
|
作者
Mousavi Movahed, Seyed Majid [1 ]
Akhavizadegan, Hamed [2 ]
Dolatkhani, Fatemeh [3 ]
Akbarpour, Samaneh [4 ]
Nejadghaderi, Seyed Aria [5 ,6 ]
Najafi, Morvarid [7 ]
Pezeshki, Parmida Sadat [7 ]
Khalili Noushabadi, Akram [8 ]
Ghasemi, Hoomaan [7 ]
机构
[1] Univ Tehran Med Sci, Sch Med, Baharloo Hosp, Tehran, Iran
[2] Univ Tehran Med Sci, Baharloo Hosp, Urol Dept, Tehran, Iran
[3] Univ Tehran Med Sci, Baharloo Hosp, Nephrol Dept, Tehran, Iran
[4] Univ Tehran Med Sci, Baharloo Hosp, Occupat Sleep Res Ctr, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Med, Tehran, Iran
[6] Univ Sci Educ & Res Network USERN, Systemat Review & Meta Anal Expert Grp SRMEG, Tehran, Iran
[7] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[8] Univ Tehran Med Sci, Baharloo Hosp, Tehran, Iran
来源
PLOS ONE | 2023年 / 18卷 / 10期
关键词
D O I
10.1371/journal.pone.0292746
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Acute kidney injury is a complication of COVID-19 and is associated with severity. Despite no specific antiviral treatment strategy, lopinavir/ritonavir and remdesivir have been used. Data on the association between AKI and receiving antiviral agents with outcomes in hospitalized patients with COVID-19 is scarce. We aimed to determine the incidence of AKI and its outcomes in COVID-19 patients with and without antiviral medications. Methods We conducted a retrospective study on hospitalized adult patients with SARS-CoV-2 infection in a tertiary center. The primary endpoint was determining mortality, intensive care unit (ICU) admission, and length of hospitalization affected by AKI development using antiviral agents. The logistic regression method was used to explore the predictive effects of AKI and antiviral therapy on composite outcomes (i.e., mortality, ICU admission, and prolonged hospitalization) in four defined groups by AKI development/not and utilizing antivirals/not. We used IBM SPSS version 24.0 software for statistical analysis. Results Out of 833 COVID-19 patients who were included, 75 patients were treated with antiviral agents and developed AKI. There was a significant difference in the occurrence of AKI and using antiviral medications (p = 0.001). Also, the group using antiviral agents and the development of AKI had the highest rate of preexisting hypertension (p = 0.002). Of note, the group of patients who used antiviral agents and also developed AKI had the most remarkable association with our composite outcome (p<0.0001), especially ICU admission (OR = 15.22; 95% CI: 8.06-27.32). Conclusions The presence of AKI among COVID-19 patients treated with antiviral agents is linked to increased severity and mortality. Therefore, it is imperative to explore preventive measures for AKI development in patients receiving antiviral therapy. Larger-scale randomized controlled trials may be warranted to provide a more comprehensive understanding of these associations.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19
    Hamilton, Patrick
    Hanumapura, Prasanna
    Castelino, Laveena
    Henney, Robert
    Parker, Kathrine
    Kumar, Mukesh
    Murphy, Michelle
    Al-Sayed, Tamer
    Pinnington, Sarah
    Felton, Tim
    Challiner, Rachael
    Ebah, Leonard
    PLOS ONE, 2020, 15 (11):
  • [32] Outcomes of Acute Kidney Injury in Colorectal Cancer Patients With COVID-19
    Olafimihan, Ayobami
    Saleem, Sania
    Omaliko, Chidiebele
    Balogun, Oluwanifemi
    Ogwor, Oghenefejiro
    Adediran, Olawale
    Fawehinmi, Praise
    Mutneja, Hemant
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S197 - S197
  • [33] Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury
    Lim, Jeong-Hoon
    Park, Sun-Hee
    Jeon, Yena
    Cho, Jang-Hee
    Jung, Hee-Yeon
    Choi, Ji-Young
    Kim, Chan-Duck
    Lee, Yong-Hoon
    Seo, Hyewon
    Lee, Jaehee
    Kwon, Ki Tae
    Kim, Shin-Woo
    Chang, Hyun-Ha
    Kim, Yong-Lim
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 15
  • [34] CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH COVID-19 WITH ACUTE KIDNEY INJURY IN ICU
    Charkviani, Mariam
    Sharma, Alisha
    Devkota, Amrit
    Padmanabhan, Shanmugha Vigneshwar
    Yadav, Kritika
    Won, Ki Seok
    Ozcekirdek, Emre
    Shrestha, Ekta
    Trongtorsak, Angkawipa
    Ozen, Ece
    Sous, Mina
    Hyser, Elise
    Friedman, Harvey
    CHEST, 2021, 160 (04) : 1022A - 1023A
  • [35] ACUTE KIDNEY INJURY (AKI) IN CANCER PATIENTS: INCIDENCE, RISK FACTORS AND OUTCOMES
    Nowshad, G.
    Alam, S.
    Shah, P.
    Lavis, V.
    Rahbar, M. H.
    Salahudeen, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2010, 58 (02) : 495 - 496
  • [36] Acute Kidney Injury in Patients with COVID-19
    Diebold, Matthias
    Schaub, Stefan
    Landmann, Emmanuelle
    Steiger, Juerg
    Dickenmann, Michael
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [37] Incidence, predictors and prognostic impact of acute kidney injury in patients with COVID-19
    Saeed, Sahrai
    Guerrot, Dominique
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2022, 38 (06) : 1413 - 1415
  • [38] Clinical Features and Outcomes of COVID-19 Patients with Acute Kidney Injury and Acute Kidney Injury on Chronic Kidney Disease
    Xu, Zhifeng
    Zhang, Yuanyuan
    Zhang, Chun
    Xiong, Fei
    Zhang, Jianduan
    Xiong, Jing
    AGING AND DISEASE, 2022, 13 (03): : 884 - 898
  • [39] Utility of Urinary Biomarkers for Diagnosis of Acute Kidney Injury (AKI) in COVID-19
    Samra, Tanvir
    Kumar, Vinod
    Ramachandran, Raja
    Mahajan, Varun
    Naik, Naveen B.
    Puri, Goverdhan Dutt
    Bhalla, Ashish
    Pal, Arnab
    Dixit, Ravi
    Kaur, Prabhjot
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2024,
  • [40] The Associations of Antihypertensive Medications, Steroids, Beta Blockers, Statins and Comorbidities with COVID-19 Outcomes in Patients with and without Chronic Kidney Disease: A Retrospective Study
    Kim, Paul
    Nadarajan, Vidhya
    Ahmed, Maham
    Furman, Katerina
    Gurm, Zoya
    Kale, Priyanka
    Khoury, Zaina
    Koussa, Sara
    Labuda, Dana
    Mekjian, Margo
    Polamarasetti, Pooja
    Simo, Leticia
    Thill, Charlotte
    Wittenberg, Sophie
    Dhar, Sorabh
    Komnenov, Dragana
    COVID, 2023, 3 (05): : 682 - 692